Jennifer Kayden Lee - 11 Feb 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of North America
Signature
/s/ Stephen Vander Stoep, Attorney-in-Fact for Jennifer Kayden Lee
Issuer symbol
RYTM
Transactions as of
11 Feb 2026
Net transactions value
$0
Form type
4
Filing time
13 Feb 2026, 17:49:52 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lee Jennifer Kayden EVP, Head of North America C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, Attorney-in-Fact for Jennifer Kayden Lee 13 Feb 2026 0001801372

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Award $0 +21,650 $0.000000 21,650 11 Feb 2026 Common Stock 21,650 Direct F1, F2
transaction RYTM Stock Options (Right to Buy) Award $0 +32,500 $0.000000 32,500 11 Feb 2026 Common Stock 32,500 $98.47 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.
F3 The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.